Evidence supporting preoperative chemotherapy for small cell carcinoma
of the bladder: A retrospective review of the M.
TTF-1 and p63 for distinguishing pulmonary small cell carcinoma
from poorly differentiated squamous cell carcinoma in previously Pap-stained cytologic material.
Small cell carcinoma
of the prostate (SCPCa), also termed neuroendocrine SCPCa, was first described by Wenk et al.
Small cell carcinoma
usually shows smearing artefacts, nuclear molding, stippled chromatin with inconspicuous nucleoli, necrotic debris and karyorrhexis.
They continue: "TTF-1 and Napsin A are a dynamic pair that can help rule out small cell carcinoma
(TTF-1 +, Napsin -) and rule in ACA simultaneously (TTF-1+, Napsin -).
Small cell carcinomas
account for 20-25% of bronchogenic carcinomas [1,2].
Histology revealed a 7 cm small cell carcinoma
of the bladder with areas of glandular differentiation invading through the muscularis propria.
These findings supported the initial cytological diagnosis of small cell carcinoma
Men with small cell carcinoma
had a significant increase in mortality, vs.
Since ACTH secretion is more prevalent in high-grade neuroendocrine tumors than in carcinoid tumors, we treated our patient with carboplatinum and etoposide, as if she had small cell carcinoma
Fiery Fred - first man to take 300 Test wickets and a former People cricket columnist - was diagnosed with small cell carcinoma
after hospital tests at Keighley, West Yorks.
Fiery Fred was diagnosed with small cell carcinoma
Overall, small cell carcinoma
of the lung is associated with the poorest prognosis of all types of lung cancer; even with treatment 5-year survival is only 5%.
A frequent complication of EGFR tyrosine kinase inhibitor therapy is the development of acquired resistance through acquisition of EGFR T790M mutations, cMET amplification, dedifferentiation of the tumor with epithelial-mesenchymal transition, or development of a small cell carcinoma
16] There is little medical literature to guide the optimal management of SCCGU malignancies and therefore treatment paradigms have by default mirrored those of the more common small cell carcinoma
of the lung.